# Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis

> **NCT06626984** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Belfast Health and Social Care Trust** · enrollment: 65 (estimated)

## Conditions studied

- Sepsis
- Fluid Overload
- Endothelial Dysfunction
- Microcirculation

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Compound sodium lactate solution

## Key facts

- **NCT ID:** NCT06626984
- **Lead sponsor:** Belfast Health and Social Care Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2024-10-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06626984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06626984, "Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06626984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*